Modulator role of neuropeptide Y in human vascular sympathetic neuroeffector junctions

  • M. Verónica Donoso
  • Ana María Delpiano
  • J. Pablo Huidobro-Toro
Part of the Experientia Supplementum book series (EXS, volume 95)


Reverse transcription polymerase chain reaction (RT-PCR) studies identified the mRNA coding for the Y1 and Y2 receptors in human mammary artery/vein and saphenous vein biopsies. Y1 receptors are expressed in vascular smooth muscles and potentiate the contractile action of sympathetic co-transmitters, adenosine triphosphate (ATP) and noradrenaline (NA); BIBP 3226, a competitive Y1 receptor antagonist, blocked the neuropeptide Y (NPY)-induced modulation. The Y2 receptor is expressed in sympathetic nerves terminals and modulates the pool of sympathetic co-transmitters released at the neuroeffector junction. NPY plays a dual role as a modulator of sympathetic co-transmission; it facilitates vascular smooth muscle reactivity and modulates the presynaptic release of ATP and NA. Sympathetic reflexes regulate human vascular resistance, where NPY plays a modulator role of paramount importance following increased sympathetic discharges, such as stress and vascular disease.


Reverse Transcription Polymerase Chain Reaction Modulator Role Sympathetic Nerve Terminal Human Saphenous Vein Sympathetic Discharge 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Tatemoto K (1982) Neuropeptide Y: complete amino acid sequence of the brain peptide. Proc Natl Acad Sci USA 79: 5485–5489PubMedGoogle Scholar
  2. 2.
    Hokfelt T, Lundberg JM, Lagercrantz H, Tatemoto K, Mutt V, Lindberg J, Terenius L, Everitt BJ, Fuxe K, Agnati L et al. (1983) Occurrence of neuropeptide Y (NPY)-like immunoreactivity in catecholamine neurons in the human medulla oblongata. Neurosci Lett 36: 217–222CrossRefPubMedGoogle Scholar
  3. 3.
    Hokfelt T, Lundberg JM, Tatemoto K, Mutt V, Terenius L, Polak J, Bloom S, Sasek C, Elde R, Goldstein M (1983) Neuropeptide Y (NPY)-and FMRFamide neuropeptide-like immunoreactivities in catecholamine neurons of the rat medulla oblongata. Acta Physiol Scand 117: 315–318PubMedGoogle Scholar
  4. 4.
    Blessing WW, Howe PR, Joh TH, Oliver JR, Willoughby JO (1986) Distribution of tyrosine hydroxylase and neuropeptide Y-like immunoreactive neurons in rabbit medulla oblongata, with attention to colocalization studies, presumptive adrenaline-synthesizing perikarya, and vagal preganglionic cells. J Comp Neurol 248: 285–300CrossRefPubMedGoogle Scholar
  5. 5.
    Lundberg JM, Terenius L, Hokfelt T, Martling CR, Tatemoto K, Mutt V, Polak J, Bloom S, Goldstein M (1982) Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function. Acta Physiol Scand 116: 477–480PubMedGoogle Scholar
  6. 6.
    Lundberg JM, Terenius L, Hokfelt T, Goldstein M (1983) High levels of neuropeptide Y in peripheral noradrenergic neurons in various mammals including man. Neurosci Lett 42: 167–172CrossRefPubMedGoogle Scholar
  7. 7.
    Edvinsson L, Emson P, McCulloch J, Tatemoto K, Uddman R (1983) Neuropeptide Y: cerebrovascular innervation and vasomotor effects in the cat. Neurosci Lett 43: 79–84CrossRefPubMedGoogle Scholar
  8. 8.
    Edvinsson L, Ekblad E, Hakanson R, Wahlestedt C (1984) Neuropeptide Y potentiates the effect of various vasoconstrictor agents on rabbit blood vessels. Br J Pharmacol 83: 519–525PubMedGoogle Scholar
  9. 9.
    Ekblad E, Edvinsson L, Wahlestedt C, Uddman R, Hakanson R, Sundler F (1984) Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers. Regul Pept 8: 225–235CrossRefPubMedGoogle Scholar
  10. 10.
    Lundberg JM, Rudehill A, Sollevi A, fried G, Wallin G (1989) Co-release of neuropeptide Y and noradrenaline from pig spleen in vivo: importance of subcellular storage, nerve impulse frequency and pattern, feedback regulation and resupply by axonal transport. Neuroscience 28: 475–486CrossRefPubMedGoogle Scholar
  11. 11.
    Lundberg JM, Tatemoto K (1982) Pancreatic polypeptide family (APP, BPP, NPY and PYY) in relation to sympathetic vasoconstriction resistant to alpha-adrenoceptor blockade. Acta Physiol Scand 116: 393–402PubMedGoogle Scholar
  12. 12.
    Allen JM, Rodrigo J, Yeats JC, Savage AP, Polak JM, Bloom SR (1984) Vascular distribution of neuropeptide Y (NPY) and effect on blood pressure. Clin Exp Hypertens 6: 1879–1882Google Scholar
  13. 13.
    Wahlestedt C, Edvinsson L, Ekblad E, Hakanson R (1985) Neuropeptide Y potentiates noradrenaline-evoked vasoconstriction: mode of action. J Pharmacol Exp Ther 234: 735–741PubMedGoogle Scholar
  14. 14.
    Wahlestedt C, Hakanson R (1986) Effects of neuropeptide Y (NPY) at the sympathetic neuroeffector junction. Can pre-and postjunctional receptors be distinguished? Med Biol 64: 85–88PubMedGoogle Scholar
  15. 15.
    Mabe Y, Tatemoto K, Huidobro-Toro JP (1985) Neuropeptide Y-induced pressor responses: activation of a non-adrenergic mechanism, potentiation by reserpine and blockade by nifedipine. Eur J Pharmacol 116: 33–39CrossRefPubMedGoogle Scholar
  16. 16.
    Westfall TC, Yang CL, Curfman-Falvey M (1995) Neuropeptide-Y-ATP interactions at the vascular sympathetic neuroef-fector junction. J Cardiovasc Pharmacol 26: 682–687PubMedGoogle Scholar
  17. 17.
    Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T (1998) XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev 50: 143–150PubMedGoogle Scholar
  18. 18.
    Larhammar D, Blomqvist AG, Yee F, Jazin E, Yoo H, Wahlested C (1992) Cloning and functional expression of a human neuropeptide Y/peptide YY receptor of the Y1 type. J Biol Chem 267: 10935–10938PubMedGoogle Scholar
  19. 19.
    Gehlert DR, Beavers LS, Johnson D, Gackenheimer SL, Schober DA, Gadski RA (1996) Expression and cloning of a human brain neuropeptide Y2 receptor. Mol Pharmacol 49: 224–228PubMedGoogle Scholar
  20. 20.
    Polak JM, Bloom SR (1984) Regulatory peptides — the distribution of two newly discovered peptides: PHI and NPY. Peptides 5: 79–89PubMedGoogle Scholar
  21. 21.
    Larsson PA, Booj S, Lundmark K, Goldstein M, Dahlstrom A (1986) Reserpine-induced effects in the adrenergic neuron as studied with cytofluorimetric scanning. Brain Res Bull 16: 63–74CrossRefPubMedGoogle Scholar
  22. 22.
    von Kugelgen I, Allgaier C, Schobert A, Starke K (1994) Co-release of noradrenaline and ATP from cultured sympathetic neurons. Neuroscience 61: 199–202Google Scholar
  23. 23.
    Hartmann D, Cesura AM, Schmid-Burgk W, Amrein R (1995) Relevance of reversible inhibitors of monoamine oxidase type A and of reuptake inhibition for noradrenaline turnover. Acta Psychiatr Scand 386: 14–21Google Scholar
  24. 24.
    Msghina M, Gonon F, Stjarne L (1998) Paired pulse analysis of ATP and noradrenaline release from sympathetic nerves of rat tail artery and mouse vas deferens: effects of K+ channel blockers. Br J Pharmacol 125: 1669–1676CrossRefPubMedGoogle Scholar
  25. 25.
    Rump LC, Von and Kugelgen I (1994) A study of ATP as a sympathetic cotransmitter in human saphenous vein. Br J Pharmacol 111: 65–72PubMedGoogle Scholar
  26. 26.
    Racchi H, Irarrazabal MJ, Howard M, Moran S, Zalaquett R, Huidobro-Toro JP (1999) Adenosine 5′-triphosphate and neuropeptide Y are co-transmitters in conjunction with noradrenaline in the human saphenous vein. Br J Pharmacol 126: 1175–1185CrossRefPubMedGoogle Scholar
  27. 27.
    Donoso MV, Miranda R, Briones R, Irarrazaval MJ, Huidobro-Toro JP (2004) Release and functional role of neuropeptide Y as a sympathetic modulator in human saphenous vein biopsies. Peptides 25: 53–64CrossRefPubMedGoogle Scholar
  28. 28.
    Donoso MV, Miranda R, Irarrazaval MJ, Huidobro-Toro JP (2004) Neuropeptide Y is released from human mammary and radial vascular biopsies and is a functional modulator of sympathetic co-transmission. J Vasc Res 41: 387–399CrossRefPubMedGoogle Scholar
  29. 29.
    Grundemar L, Hakanson R (1990) Effects of various neuropeptide Y/peptide YY fragments on electrically-evoked contractions of the rat vas deferens. Br J Pharmacol 100: 190–192PubMedGoogle Scholar
  30. 30.
    Grundemar L, Krstenansky JL, Håkanson R (1992) Activation of neuropeptide Y1 and Y2 receptors by substituted and truncated neuropeptide y analogs: identification of signal epitopes. Eur J Pharmacol 232: 271–278Google Scholar
  31. 31.
    Doods HN, Wienen W, Entzeroth M, Rudolf K, Eberlein W, Engel W, Wieland A (1995) Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226. J Pharmacol Exp Ther 275: 136–142PubMedGoogle Scholar
  32. 32.
    Sautel M, Rudolf K, Wittneben H, Herzog H, Martinez R, Munoz M, Eberlein W, Engel W, Walker P, Beck-Sickinger AG (1996) Neuropeptide Y and the non-peptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor. Mol Pharmacol 50: 285–292PubMedGoogle Scholar
  33. 33.
    Wieland HA, Engel W, Eberlein W, Rudolf K, Doods HN (1998) Subtype selectivity of the novel nonpeptide neuropeptide Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodents. Br J Pharmacol 125: 549–555CrossRefPubMedGoogle Scholar
  34. 34.
    Angus JA (1997) New insights into vascular reactivity: from altered structure to neural control. Clin Exp Pharmacol Physiol 24: 297–304PubMedGoogle Scholar
  35. 35.
    Kennedy B, Shen GH, Ziegler MG (1997) Neuropeptide Y-mediated pressor responses following high-frequency stimulation of the rat sympathetic nervous system. J Pharmacol Exp Ther 281: 291–296PubMedGoogle Scholar
  36. 36.
    Doods H, Gaida W, Wieland HA, Dollinger H, Schnorrenberg G, Esser F, Engel W, Eberlein W, Rudolf K (1999) BIIE0246: a selective and high affinity neuropeptide Y2 receptor antagonist. Eur J Pharmacol 384: R3–5CrossRefPubMedGoogle Scholar
  37. 37.
    Macho P, Perez R, Huidobro-Toro JP, Domenech RJ (1989) Neuropeptide Y (NPY): a coronary vasoconstrictor and potentiator of catecholamine-induced coronary constriction. Eur J Pharmacol 167: 67–74CrossRefPubMedGoogle Scholar
  38. 38.
    Mezzano V, Donoso MV, Capurro D, Huidobro-Toro JP (1998) Increased neuropeptide Y pressor activity in Goldblatt hypertensive rats: in vivo studies with BIBP 3226. Peptides 19: 1227–1232CrossRefPubMedGoogle Scholar
  39. 39.
    Bergdahl A, Nilsson T, Cantera L, Nilsson L, Sun XY, Hedner T, Erlinge D, Valdemarson S, Edvinsson L (1996) Neuropeptide Y potentiates noradrenaline-induced contraction through the neuropeptide Y Y1 receptor. Eur J Pharmacol 316: 59–64CrossRefPubMedGoogle Scholar
  40. 40.
    Uddman R, Moller S, Nilsson T, Nystrom S, Ekstrand J, Edvinsson L (2002) Neuropeptide Y1 and neuropeptide Y2 receptors in human cardiovascular tissues. Peptides 23: 927–934CrossRefPubMedGoogle Scholar
  41. 41.
    Doods HN, Wieland HA, Engel W, Eberlein W, Willim KD, Entzeroth M, Wienen W, Rudolf K (1996) BIBP 3226, the first selective neuropeptide Y1 receptor antagonist: a review of its pharmacological properties. Regul Pept 65: 71–77CrossRefPubMedGoogle Scholar
  42. 42.
    Erlinge D, Ekman R, Thulin T, Edvinsson L (1992) Neuropeptide Y-like immunoreactivity and hypertension. J Hypertens 10: 1221–1225PubMedGoogle Scholar
  43. 43.
    Zhao XH, Sun XY, Edvinsson L, Hedner T (1997) Does the neuropeptide Y Y1 receptor contribute to blood pressure control in the spontaneously hypertensive rat? J Hypertens 15: 19–27CrossRefPubMedGoogle Scholar
  44. 44.
    Donoso V, Silva M, St-Pierre S, Huidobro-Toro JP (1988) Neuropeptide Y (NPY), an endogenous presynaptic modulator of adrenergic neurotransmission in the rat vas deferens: structural and functional studies. Peptides 9: 545–553CrossRefPubMedGoogle Scholar
  45. 45.
    Dumont Y, Fournier A, St-Pierre S, Quirion R (1993) Comparative characterization and autoradi-ographic distribution of neuropeptide Y receptor subtypes in the rat brain. J Neurosci 13: 73–86PubMedGoogle Scholar
  46. 46.
    Capurro D, Huidobro-Toro JP (1999) The involvement of neuropeptide Y Y1 receptors in the blood pressure baroreflex: studies with BIBP 3226 and BIBO 3304. Eur J Pharmacol 376: 251–255CrossRefPubMedGoogle Scholar
  47. 47.
    Huidobro-Toro JP, Donoso MV (2004) Sympathetic co-transmission: the coordinated action of ATP and noradrenaline and their modulation by neuropeptide Y in human vascular neuroeffector junctions. Eur J Pharmacol 500: 27–35Google Scholar
  48. 48.
    Omland T, Opstad PK, Dickenstein K (1994) Plasma neuropeptide Y levels in the acute and early convalescent phase after myocardial infarction. Am Heart J 127: 774–779CrossRefPubMedGoogle Scholar
  49. 49.
    Khatun S, Kanayama N, Belayet HM, Bhuiyan AB, Jahan S, Begum A, Kobayashi T, Terao T (2000) Increased concentrations of plasma neuropeptide Y in patients with eclampsia and preeclampsia. Am J Obstet Gynecol 182: 896–900CrossRefPubMedGoogle Scholar
  50. 50.
    Adrian TE, Allen JM, Terenghi G, Bacarese-Hamilton AJ, Brown MJ, Polak JM, Bloom SR (1983) Neuropeptide Y in phaeochromocytomas and ganglioneuroblastomas. Lancet 2: 540–542PubMedGoogle Scholar
  51. 51.
    Eurin J, Barthélemy C, Masson F, Maistre G, Soualmia H, Noé E, Sarfati F, Eurin B, Carayon A (2000) Release of neuropeptide Y and hemodynamic changes during surgical removal of human pheochromocytomas. Regul Peptides 86: 95–102Google Scholar
  52. 52.
    Zukowska-Grojec Z (1995) Neuropeptide Y. A novel sympathetic stress hormone and more. Ann NY Acad Sci 771: 219–233PubMedGoogle Scholar
  53. 53.
    Fried G, Hokfelt T, Lundberg JM, Terenius L, Hamberger L (1986) Neuropeptide Y and noradrenaline in human uterus and myometrium during normal and pre-eclamptic pregnancy. Hum Reprod 1: 359–364PubMedGoogle Scholar
  54. 54.
    Ahlborg G, Weitzberg E, Sollevi A, Lundberg JM (1992) Splanic and renal vasoconstrictor and metabolic responses to neuropeptide Y in resting and exercising man. Acta Physiol Scand 145: 139–149PubMedGoogle Scholar
  55. 55.
    Kaijser L, Pernow J, Berglund B, Grunnström J, Lundberg JM (1994) Neuropeptide Y release form human heart is enhanced during prolonged exercise in hypoxia. J Appl Physiol 76: 1346–1349PubMedGoogle Scholar
  56. 56.
    Lundberg JM, Hemsen A, Fried G, Theodorsson-Norheim E, Lagercrantz H (1986) Co-release of neuropeptide Y (NPY)-like immunoreactivity and catecholamines in newborn infants. Acta Physiol Scand 126: 471–473PubMedGoogle Scholar
  57. 57.
    Corder R, Emson PC, Lowry PJ (1984) Purification and characterization of human neuropeptide Y from adrenal-medullary phaeochromocytoma tissue. Biochem J 219: 699–706PubMedGoogle Scholar
  58. 58.
    Tabarin A, Cassiède P, Minot AP, Cuber JC, Roger P, Ducassou, D (1993) Heterogeneity of neuropeptide Y immunoreactivity in patients with pheochromocytoma: influence on the diagnostic power of measuring plasma NPY using antisera with different specificities. Acta Endocrinol 128: 243–250PubMedGoogle Scholar
  59. 59.
    Hegbrant J, Thysell H, Ekman R (1995) Circulating neuropeptide Y in plasma from uremic patients consists of multiple peptide fragments. Peptides 16: 395–397CrossRefPubMedGoogle Scholar
  60. 60.
    Rang HP, Dale MM, Ritter JM, Moore PK (2003) In: Pharmacology, 5th edition, Churchill Livingstone, Elsevier Science Limited, UKGoogle Scholar
  61. 61.
    Valdecantos P, Briones R, Moya P, Germain A, Huidobro-Toro JP (2003) Pharmacological identification of P2X1, P2X4 and P2X7 nucleotide receptors in the smooth muscles of human umbilical cord and chorionic blood vessels. Placenta 24: 17–26CrossRefPubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag/Switzerland 2006

Authors and Affiliations

  • M. Verónica Donoso
    • 1
  • Ana María Delpiano
    • 1
  • J. Pablo Huidobro-Toro
    • 1
  1. 1.J.V. Luco Center for Cell Regulation and Pathology, Millenium Institute for Fundamental and Applied Biology, Dept. Physiology, Neurohumoral Regulation Unit, Faculty of Biological SciencesP. Catholic University of ChileSantiagoChile

Personalised recommendations